EUR 3 million for GMP production of clinical study material

ForTra gGmbH für Forschungstransfer der Else Kröner-Fresenius-Stiftung (ForTra) supports the legally compliant production of new pharmaceutical products under GMP conditions that will be directly used in first-in-human clinical trials.
Call for Proposals: EUR 3 million for GMP production of clinical study material

ForTra is announcing a call for proposals to produce active compounds under Good Manufacturing Practice (GMP) conditions which are intended to be subsequently utilized in a clinical study involving patients.

The implementation of clinical studies is a cost-intensive and mandatory step on the path to translating new medications into clinical application. ForTra is going to enable individual innovative projects that address a high medical need to carry out a clinical study by financially supporting the production of the given study material under GMP conditions as prescribed by law. The entire production process or individual parts thereof shall be funded for a variety of active compound classes, preferentially for molecules from the area of synthetic chemistry (“small molecules”, peptides, oligonucleotides, RNA, etc.). Up to three million euros are envisaged for the whole call for proposals.

Eligible to submit proposals for non-profit funding by ForTra are clinician and medical scientists employed by academic research facilities (hospital clinics, research institutes, etc.) or other non-profit scientific entities.

The selection procedure for funded projects occurs in two steps: Proposal outlines can be submitted via email until September 16, 2024 to Information regarding the details of proposal submission can be found among the Downloads.

An external panel of expert reviewers uses the outlines to identify individual projects whose principal investigators are subsequently requested to submit a full application. Following assessment and recommendation of the full applications by the expert reviewers and approval by the Foundation Board, ForTra will send out the positive evaluation and financing decisions presumably by the end of the year 2024.

Portrait Prof. Dr. Martin Zörnig
Prof. Dr. Martin Zörnig
Managing Director ForTra gGmbH für Forschungstransfer der EKFS